335619-18-6

Inakalant is an atrial specific potassium channel blocker with antiarrhythmic activity. Inakalant works by selectively blocking potassium channels in heart cells, thereby prolongs the action potential duration (APD) of cardiomyocytes and increases the effective refractory period of the atria and ventricles, which helps to terminate and prevent the occurrence of arrhythmias such as atrial fibrillation (AF). Inakalant can be used in the study of arrhythmia and cardiac electrophysiology[1].

[1] Edvardsson N, et al. Inverse correlation between the atrial fibrillatory rate and the ventricular repolarization time: observations at baseline and after an intravenous infusion of a combined potassium and sodium current blocker[J]. Annals of Noninvasive Electrocardiology, 2016, 21(3): 236-245. DOI:10.1111/anec.12300